Shahar Harel serves as the Head of AI at Quris, a company applying a novel bio-AI approach to transform drug development. Using Patients-on-a-Chip, they generate a proprietary dataset to train machine learning models in predicting drug safety and efficacy. This disruptive method employs automated, high-throughput testing of drugs on miniaturized Patients-on-a-Chip, enhanced by continuous monitoring with nano-sensors. Leveraging stem cell-derived Patients-on-a-Chip from a collaboration with the New York Stem Cell Foundation, Quris aims to revolutionize the accuracy of predicting clinical outcomes for drug candidates.